Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Busulfan"" wg kryterium: Temat


Tytuł :
Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
Autorzy :
Jansing T; Faculty of Pharmacy, Siam University, Bangkok, Thailand.
Sanpakit K; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Tharnpanich T; Department of Pharmacy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Jiranantakan T; Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Niphandwongkorn V; Department of Nurse, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chindavijak B; Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Suansanae T; Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Pokaż więcej
Źródło :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 May; Vol. 38 (4), pp. 346-357. Date of Electronic Publication: 2021 Mar 03.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Busulfan/*therapeutic use
Myeloablative Agonists/*therapeutic use
Administration, Intravenous ; Adolescent ; Busulfan/administration & dosage ; Busulfan/blood ; Child ; Child, Preschool ; Drug Monitoring ; Female ; Humans ; Male ; Myeloablative Agonists/administration & dosage ; Myeloablative Agonists/blood ; Pilot Projects ; Thailand ; Transplantation Conditioning
Czasopismo naukowe
Tytuł :
Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?
Autorzy :
Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 May; Vol. 100 (5), pp. 1349-1350. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Letter; Comment
MeSH Terms :
Busulfan*
Hematopoietic Stem Cell Transplantation*
Cyclophosphamide ; Liver
Opinia redakcyjna
Tytuł :
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Autorzy :
Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA. .
Singh V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, 48201, USA.
Ayash L; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Deol A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Ratanatharathorn V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Uberti JP; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 969-978. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Antilymphocyte Serum/*therapeutic use
Busulfan/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*therapeutic use
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Aged ; Allografts ; Busulfan/adverse effects ; Female ; Graft vs Host Disease/etiology ; Humans ; Infections/epidemiology ; Lymphocyte Depletion ; Male ; Middle Aged ; Mycophenolic Acid/therapeutic use ; Myeloablative Agonists/adverse effects ; Progression-Free Survival ; Retrospective Studies ; T-Lymphocytes ; Tacrolimus/therapeutic use ; Treatment Outcome ; Unrelated Donors ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning.
Autorzy :
McCune JS; City of Hope, Department of Population Sciences, Duarte, California 91010, United States.; City of Hope, Department of Hematology & HCT, Duarte, California 91010, United States.
McKiernan JS; City of Hope, Department of Population Sciences, Duarte, California 91010, United States.
van Maarseveen E; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, 3584 CS Utrecht, The Netherlands.
Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, 3584 CS Utrecht, The Netherlands.; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Randolph TW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.
Deeg HJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.; Department of Medicine, University of Washington, Seattle, Washington 98195, United States.
Nakamura R; City of Hope, Department of Hematology & HCT, Duarte, California 91010, United States.
Baker KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.; Department of Pediatrics, University of Washington, Seattle, Washington 98195, United States.
Pokaż więcej
Źródło :
Journal of proteome research [J Proteome Res] 2021 Jan 01; Vol. 20 (1), pp. 684-694. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Busulfan*/therapeutic use
Graft vs Host Disease*/diagnosis
Hematopoietic Stem Cell Transplantation*
Metabolomics*
Humans ; Prognosis ; Recurrence ; Transplantation Conditioning ; Vidarabine
Czasopismo naukowe
Tytuł :
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Autorzy :
Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Gerull S; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Halter J; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Heim D; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Chalandon Y; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Levrat SM; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Schanz U; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Nair G; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Ansari M; Department Women, Children and Adolescent, Unit of Oncology and Hematology Pediatric, University Hospital of Geneva, Geneva, Switzerland.; Cansearch Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Simon P; Clinical Trials Unit, Department of Clinical Research, Basel University, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Cantoni N; Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 209-216. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Busulfan/*administration & dosage
Cyclophosphamide/*administration & dosage
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Immunosuppressive Agents/*administration & dosage
Transplantation Conditioning/*methods
Adult ; Aged ; Busulfan/adverse effects ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/mortality ; Cyclophosphamide/adverse effects ; Drug Therapy, Combination ; Female ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/mortality ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality ; Young Adult
Czasopismo naukowe
Tytuł :
Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Autorzy :
Esteves I; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Santos FPS; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Ribeiro AAF; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Seber A; Hospital Samaritano, São Paulo, Brazil.
Sugawara EK; Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil.
Sobrinho JJDN; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Barros JC; Transplantation, Hospital Dr. Euryclides de Jesus Zerbini, São Paulo, Brazil.
Oliveira JSR; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Fernandes JF; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Bone Marrow Transplantation Unit, Itaci Hospital, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Hamerschlak N; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
de Lima M; Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, USA.
Kerbauy FR; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 773-781. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan/*administration & dosage
Busulfan/*adverse effects
Hepatic Veno-Occlusive Disease/*etiology
Transplantation Conditioning/*adverse effects
Administration, Intravenous ; Administration, Oral ; Adolescent ; Area Under Curve ; Busulfan/pharmacokinetics ; Child ; Child, Preschool ; Controlled Clinical Trials as Topic ; Disease Susceptibility ; Female ; Hematologic Diseases/diagnosis ; Hematologic Diseases/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hepatic Veno-Occlusive Disease/diagnosis ; Hepatic Veno-Occlusive Disease/epidemiology ; Hepatic Veno-Occlusive Disease/mortality ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Prognosis ; Transplantation Conditioning/methods ; Young Adult
Czasopismo naukowe
Tytuł :
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
Autorzy :
Wada F; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Nishikori M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. .
Hishizawa M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Watanabe M; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Aiba A; Department of Hematology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Kitano T; Department of Hematology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Shimazu Y; Department of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Shindo T; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Kondo T; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Nov; Vol. 112 (5), pp. 609-613. Date of Electronic Publication: 2020 Sep 26.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan/*adverse effects
Central Nervous System Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*adverse effects
Lymphoma/*therapy
Thiotepa/*adverse effects
Thrombocytopenia/*etiology
Transplantation Conditioning/*adverse effects
Adult ; Aged ; Busulfan/administration & dosage ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Male ; Middle Aged ; Thiotepa/administration & dosage ; Time Factors ; Transplantation Conditioning/methods ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Autorzy :
Uchida N; Department of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. .
Matsumoto K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Sakura T; Department of Hematology, Saiseikai Maebashi Hospital, Gunma, Japan.
Hidaka M; Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Miyamoto T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Eto T; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Maeda Y; Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Murayama T; Department of Hematology, Hyogo Cancer Center, Hyogo, Japan.
Fujishima N; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Yoshimoto G; Department of Hematology, National Kyushu Medical Center, Fukuoka, Japan.
Morita K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Kishimoto J; Department of Research and Development of Next Generation Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Teshima T; Department of Hematology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.
Taniguchi S; Department of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Yamashita T; Division of Hematology and Oncology, St. Luke's International Hospital, Tokyo, Japan.
Mori SI; Division of Hematology and Oncology, St. Luke's International Hospital, Tokyo, Japan.
Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Harada M; Department of Hematology, Karatsu Higashimatsuura Medical Association, Saga, Japan.
Pokaż więcej
Corporate Authors :
Japan Study Group for Cell Therapy, Transplantation (JSCT)
Źródło :
International journal of hematology [Int J Hematol] 2020 Oct; Vol. 112 (4), pp. 510-523. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan/*administration & dosage
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*therapy
Myelodysplastic Syndromes/*therapy
Transplantation Conditioning/*methods
Age Factors ; Aged ; Busulfan/adverse effects ; Clinical Trials, Phase II as Topic ; Disease-Free Survival ; Female ; Humans ; Infusions, Intravenous ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Prospective Studies ; Radiation Dosage ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Whole-Body Irradiation/methods
Czasopismo naukowe
Tytuł :
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Autorzy :
Shargian-Alon L; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel. .; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. .
Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rozovski U; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yahav D; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Infectious Disease Unit, Rabin Medical Center, Petah-Tikva, Israel.
Sela-Navon M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Rubinstein M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Oniashvilli N; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; The Raphael Recanati Genetic Institute, Rabin Medical Center, Petah-Tikva, Israel.
Pasvolsky O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yeshurun M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2939-2945. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Busulfan/*analogs & derivatives
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Busulfan/administration & dosage ; Cohort Studies ; Cytarabine/administration & dosage ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Idarubicin/administration & dosage ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Vidarabine/administration & dosage ; Young Adult
SCR Protocol :
Ida-FLAG protocol
Czasopismo naukowe
Tytuł :
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Autorzy :
Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Barbui T; Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1599-1613. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Polycythemia Vera*/diagnosis
Polycythemia Vera*/drug therapy
Polycythemia Vera*/genetics
Polycythemia Vera*/mortality
Thrombocythemia, Essential*/diagnosis
Thrombocythemia, Essential*/drug therapy
Thrombocythemia, Essential*/genetics
Thrombocythemia, Essential*/mortality
Aspirin/*therapeutic use
Busulfan/*therapeutic use
Interferon-alpha/*therapeutic use
Age Factors ; Aspirin/adverse effects ; Busulfan/adverse effects ; Calreticulin/genetics ; Disease-Free Survival ; Humans ; Interferon-alpha/adverse effects ; Janus Kinase 2/genetics ; Mutation ; Receptors, Thrombopoietin/genetics ; Risk Assessment ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Successful Salvage Treosulfan-Based Megachemotherapy With Allogeneic Stem Cell Transplantation in Nonsyndromic, Therapy-Resistant Disseminated Juvenile Xanthogranuloma: A Case Report.
Autorzy :
Janeczko-Czarnecka M; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Raciborska A; Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.
Gos M; Medical Genetics Department, Institute of Mother and Child, Warsaw, Poland.
Kordowska O; Medical Genetics Department, Institute of Mother and Child, Warsaw, Poland.
Gajek K; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Rybka B; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Ryczan-Krawczyk R; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Kałwak K; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Ussowicz M; Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland. Electronic address: .
Pokaż więcej
Źródło :
Transplantation proceedings [Transplant Proc] 2020 Nov; Vol. 52 (9), pp. 2844-2848. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Busulfan/*analogs & derivatives
Combined Modality Therapy/*methods
Hematopoietic Stem Cell Transplantation/*methods
Salvage Therapy/*methods
Xanthogranuloma, Juvenile/*therapy
Antineoplastic Agents, Alkylating/therapeutic use ; Busulfan/therapeutic use ; Child, Preschool ; Humans ; Male ; Remission Induction ; Xanthogranuloma, Juvenile/complications
Czasopismo naukowe
Tytuł :
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.
Autorzy :
Saini N; Department of Stem Cell Transplantation and Cellular Therapy.
Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy.
Milton DR; Department of Biostatistics.
Tang G; Department of Hematopathology, and.
Delgado R; Department of Stem Cell Transplantation and Cellular Therapy.
Rondon G; Department of Stem Cell Transplantation and Cellular Therapy.
Popat UR; Department of Stem Cell Transplantation and Cellular Therapy.
Hosing CM; Department of Stem Cell Transplantation and Cellular Therapy.
Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy.
Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy.
Alousi AM; Department of Stem Cell Transplantation and Cellular Therapy.
Mehta R; Department of Stem Cell Transplantation and Cellular Therapy.
Srour S; Department of Stem Cell Transplantation and Cellular Therapy.
Khouri IF; Department of Stem Cell Transplantation and Cellular Therapy.
Weber DM; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Thomas SK; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Lee HC; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Patel KK; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy.
Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2020 Oct 13; Vol. 4 (19), pp. 4834-4837.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan*
Hematopoietic Stem Cell Transplantation*
Melphalan ; Transplantation Conditioning ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Towards new long-term composite 'Quality of Survival' endpoints.
Autorzy :
Boelens JJ; Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2020 Oct; Vol. 55 (10), pp. 1898-1899. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Busulfan*
Hematopoietic Stem Cell Transplantation*
Acute Disease ; Child ; Humans ; Retrospective Studies ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
A rapid HPLC-MS/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation.
Autorzy :
Jinjie Y; Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Sun N; Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Zhang S; Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Feng X; Phase I Clinical trials Centre, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China.
Chen X; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Zhao D; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Zhao L; Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło :
Biomedical chromatography : BMC [Biomed Chromatogr] 2020 Sep; Vol. 34 (9), pp. e4898. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Busulfan/*blood
Chromatography, High Pressure Liquid/*methods
Tandem Mass Spectrometry/*methods
Blood Specimen Collection ; Busulfan/pharmacokinetics ; Busulfan/therapeutic use ; Child ; Child, Preschool ; Drug Monitoring/methods ; Female ; Hemolysis ; Humans ; Immunosuppressive Agents/blood ; Immunosuppressive Agents/pharmacokinetics ; Immunosuppressive Agents/therapeutic use ; Linear Models ; Male ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
Autorzy :
Salman B; Pharmacy Department, Sultan Qaboos University Hospital, Muscat, Oman.
Al-Khabori M; Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman. .
Al-Huneini M; Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman.
Al-Rawas A; Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.
Dennison D; Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman.
Al-Za'abi M; Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Aug; Vol. 112 (2), pp. 210-216. Date of Electronic Publication: 2020 May 28.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan/*adverse effects
Busulfan/*metabolism
Hematopoietic Stem Cell Transplantation/*adverse effects
Hepatic Veno-Occlusive Disease/*diagnosis
Hepatic Veno-Occlusive Disease/*etiology
Adolescent ; Adult ; Biomarkers/metabolism ; Busulfan/administration & dosage ; Child ; Female ; Hematologic Neoplasms/therapy ; Hepatic Veno-Occlusive Disease/drug therapy ; Humans ; Male ; Middle Aged ; Negative Results ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.
Autorzy :
Shukla P; Department of Clinical Pharmacy, University of California San Francisco, 600 16th Street, Room N474F, San Francisco, CA 94158-0622, USA.
Dvorak CC; Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco, Benioff Children's Hospital, 550 16th Street, Floor 4, San Francisco, CA 94143-0434, USA.
Long-Boyle J; Department of Clinical Pharmacy, University of California San Francisco, 600 16th Street, Room N474F, San Francisco, CA 94158-0622, USA.; Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco, Benioff Children's Hospital, 550 16th Street, Floor 4, San Francisco, CA 94143-0434, USA.
Kharbanda S; Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco, Benioff Children's Hospital, 550 16th Street, Floor 4, San Francisco, CA 94143-0434, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Aug 06; Vol. 21 (16). Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Case Reports
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Busulfan/*therapeutic use
Mucopolysaccharidosis I/*therapy
Area Under Curve ; Busulfan/pharmacokinetics ; Child ; Chimerism ; Female ; Hematopoietic Stem Cells/cytology ; Humans ; Iduronidase/blood ; Infant ; Male ; Mucopolysaccharidosis I/blood ; Tissue Donors ; Transplantation Conditioning ; Treatment Outcome
Raport
Tytuł :
Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Autorzy :
Huttunen P; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Taskinen M; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Vettenranta K; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Pokaż więcej
Źródło :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2020 Aug; Vol. 37 (5), pp. 355-364. Date of Electronic Publication: 2020 Mar 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*adverse effects
Busulfan/*analogs & derivatives
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*adverse effects
Adolescent ; Antineoplastic Agents/therapeutic use ; Busulfan/adverse effects ; Busulfan/therapeutic use ; Child ; Child, Preschool ; Cyclophosphamide/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Infant ; Male ; Myeloablative Agonists/adverse effects ; Myeloablative Agonists/therapeutic use ; Retrospective Studies ; Transplantation Conditioning/methods ; Transplantation, Homologous ; Treatment Outcome ; Whole-Body Irradiation/methods
Czasopismo naukowe
Tytuł :
Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".
Autorzy :
Dupuis LL; Department of Pharmacy and Research Institute, The Hospital for Sick Children and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Quinones CM; Department of Population Sciences, Beckman Research Institute at City of Hope, Duarte, CA, USA.
Ritchie J; Pathology & Laboratory Medicine Department, Emory University, Atlanta, GA, USA.
Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Pediatrics, University of Washington, Seattle, WA, USA.
Bauters T; Chair, European Society for Blood and Marrow Transplantation (EBMT) Pharmacist Committee, Pediatric Hemato-Oncology & Stem Cell Transplantation, Ghent University Hospital, Belgium.
Yeh RF; Pharmacokinetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.
Anasetti C; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Boelens JJ; Chief, Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hamerschlak N; Hematology and Bone Marrow Transplantation Department, Hospital Israelita Albert Einstein, São Paulo Area, Brazil.
Hassan M; Division of Experimental Cancer Medicine, Department of Laboratory Medicine at Karolinska Institutet and Division of Clinical Research Centrum at Karolinska University Hospital, Stockholm, Sweden.
Kang HJ; Department of Pediatrics, Seoul National Univeristy College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Korea.
Kanda Y; Division of Hematology, Department of Medicine, Jichi Medical University and Division of Hematology, Saitama Medical Center, Jichi Medical University, Japan.
Paci A; Department of Pharmacology, Institute Gustave Roussy Cancer Center, Grand Paris, School of Pharmacy - Paris Sud University, France.
Perales MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Shaw PJ; BMT Services, The Children's Hospital at Westmead, Westmead, New South Wales, and Discipline of Child and Adolescent Health, University of Sydney, Australia.
Seewaldt VL; Department of Population Sciences, Beckman Research Institute at City of Hope, Duarte, CA, USA.
Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Militano O; Pharmacist, Children's Oncology Group.
Pulsipher MA; Transplantation and Cellular Therapy Section, Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, CA, USA.
McCune JS; Department of Population Sciences, Beckman Research Institute at City of Hope, Duarte, CA, USA. Electronic address: .
Pokaż więcej
Źródło :
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2020 Sep; Vol. 26 (9), pp. e235-e236. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :
Letter; Comment
MeSH Terms :
Busulfan*
Plasma*
Consensus ; Humans
Opinia redakcyjna
Tytuł :
Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".
Autorzy :
Kawedia JD; Pharmacy Clinical Programs, Pharmacy Division, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: .
Handy VW; Pharmacy Clinical Programs, Pharmacy Division, University of Texas MD Anderson Cancer Center, Houston, Texas.
Shigle TL; Pharmacy Clinical Programs, Pharmacy Division, University of Texas MD Anderson Cancer Center, Houston, Texas.
Gulbis AM; Pharmacy Clinical Programs, Pharmacy Division, University of Texas MD Anderson Cancer Center, Houston, Texas.
Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2020 Sep; Vol. 26 (9), pp. e232-e234. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Letter; Comment
MeSH Terms :
Busulfan*
Plasma*
Consensus ; Humans
Opinia redakcyjna
Tytuł :
Treosulfan-based conditioning in HSCT patients.
Autorzy :
Veys P; Blood and Marrow Transplantation, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, London, United Kingdom.; University College London GOS Institute of Child Health and National Institute for Health Research GOS Hospital Biomedical Research Centre, London, United Kingdom.
Veys D; St. John's College Cambridge, Cambridge, United Kingdom.
Pokaż więcej
Źródło :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2020 Aug; Vol. 37 (5), pp. 353-354. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Busulfan*/analogs & derivatives
Hematopoietic Stem Cell Transplantation*
Humans ; Transplantation Conditioning
Czasopismo naukowe
Tytuł :
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
Autorzy :
Hsu J; Weill Cornell Medical Center/New York Presbyterian Hospital, Department of Medicine, Division of Hematology/Oncology, New York, NY, USA.
Van Besien K; Weill Cornell Medical Center/New York Presbyterian Hospital, Department of Medicine, Division of Hematology/Oncology, New York, NY, USA.
Baron F; Laboratory of Hematology, University of Liege and CHU of Liège, Liège, Belgium.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1529-1534. Date of Electronic Publication: 2020 May 30.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Busulfan*
Leukemia, Myeloid, Acute*
Humans ; Melphalan ; Transplantation Conditioning ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł :
UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring.
Autorzy :
Matar KM; Department of Pharmacology & Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait, Kuwait. .
Alshemmari SH; Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait, Kuwait.
Refaat S; Department of Medical Oncology, Kuwait Cancer Control Center, Kuwait, Kuwait.
Anwar A; Department of Pharmacology & Toxicology, Faculty of Medicine, Kuwait University, Kuwait, Kuwait.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Jun 02; Vol. 10 (1), pp. 8913. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*blood
Busulfan/*blood
Chromatography, High Pressure Liquid/*methods
Tandem Mass Spectrometry/*methods
Adolescent ; Adult ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/therapeutic use ; Busulfan/administration & dosage ; Busulfan/therapeutic use ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Female ; Hematologic Neoplasms/drug therapy ; Humans ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
Autorzy :
Ussowicz M; Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland. .
Pokaż więcej
Źródło :
Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2020 Jun; Vol. 56 (6), pp. 389-403.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Busulfan/*analogs & derivatives
Vidarabine/*analogs & derivatives
Busulfan/adverse effects ; Busulfan/therapeutic use ; Drug Combinations ; Humans ; Vidarabine/adverse effects ; Vidarabine/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies